Chemoimmunotherapy Followed by Residual Tumor Radiation for Extensive Stage Small-cell Lung Cancer

What this Trial Is About

Researchers are evaluating the impact of combining chemotherapy, immunotherapy, and targeted radiation on patients with extensive stage small cell lung cancer, a condition known for initial sensitivity to treatment but eventual resistance. The study aims to assess how adding radiation to residual tumor areas after chemoimmunotherapy affects progression-free survival and overall survival. This phase II trial also monitors the treatments response rate and potential side effects. Participants receive a combination of carboplatin, adebrelimab, and etoposide intravenously in cycles every 28 days, up to four cycles if there is no disease progression or unacceptable toxicity. Following chemotherapy and immunotherapy, residual tumors are treated with external beam radiation totaling 50 Gy delivered in 25 fractions. This sequential approach aims to address remaining tumor cells and possibly extend drug resistance. During the study, patients undergo regular assessments including tumor measurements based on RECIST 1.1 criteria, blood tests for counts and organ function, and monitoring for adverse effects. Researchers track progression-free survival over 24 months and overall survival over 36 months. Participation involves scheduled treatments and evaluations to measure how well the combined therapy controls the cancer and its safety profile, with the study continuing until March 2027.

Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer